NCT06778187 2025-06-10Oral-ATO for TP53-mutated Myeloid MalignanciesThe University of Hong KongPhase 2 Recruiting30 enrolled
NCT00020969 2020-10-05Arsenic Trioxide in Treating Patients With Myelodysplastic SyndromesCTI BioPharmaPhase 2 Terminated
NCT00104806 2018-08-10Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic SyndromesWake Forest University Health SciencesPhase 2 Terminated5 enrolled
NCT00274781 2015-07-10Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic SyndromesThe Cleveland ClinicPhase 2 Completed30 enrolled 7 charts